Acurx Pharmaceuticals (Acurx Pharmaceuticals) Net Cash per Share : $0.31 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Acurx Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 was $0.31.

The historical rank and industry rank for Acurx Pharmaceuticals's Net Cash per Share or its related term are showing as below:

ACXP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.63 Med: 6.52 Max: 12.35
Current: 6.35

During the past 5 years, the highest Price-to-Net-Cash Ratio of Acurx Pharmaceuticals was 12.35. The lowest was 3.63. And the median was 6.52.

ACXP's Price-to-Net-Cash is ranked worse than
63.82% of 868 companies
in the Biotechnology industry
Industry Median: 4.22 vs ACXP: 6.35

Acurx Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for Acurx Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals Net Cash per Share Chart

Acurx Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

0.10

0.28

1.19

0.61

0.31

Acurx Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Cash per Share	Get a 7-Day Free Trial												0.61	0.44	0.47	0.29	0.31

Competitive Comparison of Acurx Pharmaceuticals's Net Cash per Share

For the Biotechnology subindustry, Acurx Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acurx Pharmaceuticals's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Acurx Pharmaceuticals's Price-to-Net-Cash falls into.

Acurx Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Acurx Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7.474	-	3.042	-	0)	/	14.4682
=	0.31

Acurx Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7.474	-	3.042	-	0)	/	14.4682
=	0.31

Acurx Pharmaceuticals (NAS:ACXP) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Acurx Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acurx Pharmaceuticals (Acurx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

3ZO:Germany

Address

259 Liberty Avenue, Staten Island, NY, USA, 10305

Website

https://www.acurxpharma.com

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Executives

David P Luci	director, 10 percent owner, officer: President and CEO
Robert J Deluccia	director, 10 percent owner	40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Carl Sailer	director	4 GREENBRIAR LANE, MONTVALE NJ 07645
Thomas L Harrison	director
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jack H Dean	director	C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Robert G. Shawah	officer: Chief Financial Officer	C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004
James J. Donohue	director	C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305